CliffBio
small molecule

HYDROCHLOROTHIAZIDE

HYDROCHLOROTHIAZIDE

Loss of exclusivity—loss of exclusivity
CompanyHIKMA INTERNATIONAL PHARMACEUTICALS LLC

Drug detail

Brand nameHYDROCHLOROTHIAZIDE
Active ingredientHYDROCHLOROTHIAZIDE
Strength12.5MG
Dosage formCAPSULE
RouteORAL
ModalitySmall molecule
FDA approvalNovember 2007
Marketing statusDISCN

More from HIKMA INTERNATIONAL PHARMACEUTICALS LLC

Source: FDA Orange Book, layered on the CliffBio company graph. Cliff dates are the loss of exclusivity; estimates are projections, not legal advice.

HYDROCHLOROTHIAZIDE patent cliff — loss of exclusivity — | CliffBio